FATIGUE, SLEEP AND CIRCADIAN RHYTHMS AT BASELINE AND AFTER THE FIRST ADJUVANT BREAST CANCER CHEMOTHERAPY TREATMENT WITHIN A RANDOMIZED CONTROL TRIAL

2.50
Hdl Handle:
http://hdl.handle.net/10755/165370
Category:
Abstract
Type:
Presentation
Title:
FATIGUE, SLEEP AND CIRCADIAN RHYTHMS AT BASELINE AND AFTER THE FIRST ADJUVANT BREAST CANCER CHEMOTHERAPY TREATMENT WITHIN A RANDOMIZED CONTROL TRIAL
Author(s):
Berger, Ann; Fischer, Patricia; Farr, Lynne; Kuhn, Bret; Argawal, Sangeeta
Author Details:
Ann Berger, PhD, RN, AOCN, FAAN, Associate Professor & Advanced Practice Nurse, University of Nebraska Medical Center, Omaha, Nebraska, USA, email: aberger@unmc.edu; Patricia Fischer, Lynne Farr, Bret Kuhn, and Sangeeta Argawal
Abstract:
Topic: Interventions to manage fatigue during and after adjuvant breast cancer chemotherapy are needed to control this distressing symptom. Purpose: To evaluate the immediate impact of a tailored behavioral sleep intervention (BSI), delivered two days before the first chemotherapy treatment, on fatigue, sleep and circadian rhythms. Managing fatigue is an ONS research priority. Framework: Piper's Integrated Fatigue Model. Methods: Randomized control trial comparing a behavioral sleep intervention to a healthy eating control group; N=93, post-operative, with Stage I/II/IIIA breast cancer, receiving adjuvant chemotherapy; mean age =51; most were married and employed. Piper Fatigue Scale (PFS), Pittsburgh Sleep Quality Index (PSQI), wrist actigraphy for 24-hour sleep/wake patterns (2 days baseline plus 7 days after chemotherapy); descriptive statistics, correlations, RM-ANOVA. Findings: At baseline, there were no group differences on demographics; nor on PFS [ microunit =2.44(1.92)] or PSQI [ micro unit =6.66(3.39)]. PSQI score was >5 in 57% and >8 in 26% of subjects. Actigraphy data showed no group differences on total sleep time, percent time awake and number of night awakenings; minutes awake after sleep onset (WASO) [ microunit=55.4(52.5)] was prolonged. After chemotherapy, mean PFS rose to 4.76(2.53). Actigraphy data showed non-significant increases in the sleep variables; WASO remained prolonged [ microunit =74.9(70.1)]. Baseline circadian rhythm variables were: mesor [ microunit =134.08(34.84)], amplitude micro unit=98.04(33.77)] and measure of robustness [ micro unit =.61(.13)]. After chemotherapy, they dropped 7-17%: mesor [ micro unit =111.26(26.56], amplitude [ micro unit =87.62(24.76), and measure of robustness [ micro unit =0.57(.11)]. The intervention group had significantly higher daily amplitude both at baseline and after chemotherapy and no significant group effect was observed [F(1,81)=2.24, p=.14]. Baseline PFS was related to PSQI (r = .34, p<.001). Day +3 fatigue was inversely correlated with daily amplitude (r= -.30, p=.05) and with goodness of fit (r= -.343, p =.03).Only amplitude was found to be different between the two groups; higher fatigue was associated with poorer subjective sleep. After chemotherapy, higher fatigue is associated with less robust day and night circadian rhythms. Short-term will be compared to long-term results of BSI on reducing fatigue and maintaining quality sleep.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2006
Conference Name:
31st Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Boston, Massachusetts, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleFATIGUE, SLEEP AND CIRCADIAN RHYTHMS AT BASELINE AND AFTER THE FIRST ADJUVANT BREAST CANCER CHEMOTHERAPY TREATMENT WITHIN A RANDOMIZED CONTROL TRIALen_GB
dc.contributor.authorBerger, Annen_US
dc.contributor.authorFischer, Patriciaen_US
dc.contributor.authorFarr, Lynneen_US
dc.contributor.authorKuhn, Breten_US
dc.contributor.authorArgawal, Sangeetaen_US
dc.author.detailsAnn Berger, PhD, RN, AOCN, FAAN, Associate Professor & Advanced Practice Nurse, University of Nebraska Medical Center, Omaha, Nebraska, USA, email: aberger@unmc.edu; Patricia Fischer, Lynne Farr, Bret Kuhn, and Sangeeta Argawalen_US
dc.identifier.urihttp://hdl.handle.net/10755/165370-
dc.description.abstractTopic: Interventions to manage fatigue during and after adjuvant breast cancer chemotherapy are needed to control this distressing symptom. Purpose: To evaluate the immediate impact of a tailored behavioral sleep intervention (BSI), delivered two days before the first chemotherapy treatment, on fatigue, sleep and circadian rhythms. Managing fatigue is an ONS research priority. Framework: Piper's Integrated Fatigue Model. Methods: Randomized control trial comparing a behavioral sleep intervention to a healthy eating control group; N=93, post-operative, with Stage I/II/IIIA breast cancer, receiving adjuvant chemotherapy; mean age =51; most were married and employed. Piper Fatigue Scale (PFS), Pittsburgh Sleep Quality Index (PSQI), wrist actigraphy for 24-hour sleep/wake patterns (2 days baseline plus 7 days after chemotherapy); descriptive statistics, correlations, RM-ANOVA. Findings: At baseline, there were no group differences on demographics; nor on PFS [ microunit =2.44(1.92)] or PSQI [ micro unit =6.66(3.39)]. PSQI score was &gt;5 in 57% and &gt;8 in 26% of subjects. Actigraphy data showed no group differences on total sleep time, percent time awake and number of night awakenings; minutes awake after sleep onset (WASO) [ microunit=55.4(52.5)] was prolonged. After chemotherapy, mean PFS rose to 4.76(2.53). Actigraphy data showed non-significant increases in the sleep variables; WASO remained prolonged [ microunit =74.9(70.1)]. Baseline circadian rhythm variables were: mesor [ microunit =134.08(34.84)], amplitude micro unit=98.04(33.77)] and measure of robustness [ micro unit =.61(.13)]. After chemotherapy, they dropped 7-17%: mesor [ micro unit =111.26(26.56], amplitude [ micro unit =87.62(24.76), and measure of robustness [ micro unit =0.57(.11)]. The intervention group had significantly higher daily amplitude both at baseline and after chemotherapy and no significant group effect was observed [F(1,81)=2.24, p=.14]. Baseline PFS was related to PSQI (r = .34, p&lt;.001). Day +3 fatigue was inversely correlated with daily amplitude (r= -.30, p=.05) and with goodness of fit (r= -.343, p =.03).Only amplitude was found to be different between the two groups; higher fatigue was associated with poorer subjective sleep. After chemotherapy, higher fatigue is associated with less robust day and night circadian rhythms. Short-term will be compared to long-term results of BSI on reducing fatigue and maintaining quality sleep.en_GB
dc.date.available2011-10-27T12:17:19Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:17:19Z-
dc.conference.date2006en_US
dc.conference.name31st Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationBoston, Massachusetts, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.